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Primate lentiviruses such as human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) are phenotypi-
cally diverse, and virus isolates vary in cytopathicity, replication rate, and cell tropism. While all virus isolates infect primary
peripheral blood lymphocytes, only a subset of strains infect established CD4-expressing T-cell lines. Here, we describe
the development and characterization of a macaque cell line that can be infected by all of the strains of SIV that we have
tested, including macrophage- and T-cell-tropic strains, primary and cell-line adapted strains, and SIVmac, SIVMne, and
SIVsm isolates. The cells can be infected by strains of HIV type 2 (HIV-2) to varying degrees, but not by either cloned or
primary isolates of HIV type 1 (HIV-1). This cell line is a derivative of a rhesus macaque mammary tumor cell line (CMMT)
engineered to express human CD4. For these studies, a CMMT-CD4 clone expressing an integrated copy of a truncated
HIV-1 long terminal repeat fused to the b-galactosidase gene (LTR-b-gal) was established to allow detection of infectious
SIV after a single round of replication. Here, we demonstrate the ability of the CMMT-CD4-LTR-b-gal cell line to rapidly
and quantitatively detect infectious SIV. Using these cells to assay virus, we could readily measure neutralizing antibody
activity in animals infected with different SIV isolates. Neutralizing activity was detected against the homologous virus and
lower, but detectable, activity was measured against heterologous virus. Thus, this system, which is highly sensitive and
can detect infection by all of the SIV isolates we tested, is a rapid method for detecting infectious virus and quantitating
neutralizing antibody activity. q 1995 Academic Press, Inc.
INTRODUCTION Wehrly, 1988; Felber and Pavlakis, 1988; Nara et al., 1987)
are each effective with only a limited subset of HIV-1
Lentiviruses such as human immunodeficiency virus isolates. Rocancourt et al. (1990) and, more recently,
(HIV) and simian immunodeficiency virus (SIV) are char- Kimpton and Emerman (1992) developed a rapid method
acterized by a high degree of genotypic and phenotypic of detecting HIV-1 based on the viral activation of an
diversity (reviewed in Cheng-Mayer, 1990; Fenyo¨ et al., integrated LTR-b-galactosidase (LTR-b-gal) gene in
1989; Zack and Overbaugh, 1994). For example, in human CD4/ HeLa cells. This assay exploits the ability of the
T-cell lines, primate lentiviruses display distinct differ- HIV Tat protein to transactivate the b-gal gene driven by
ences in host cell specificity, replication rate, and cell the HIV-1 long terminal repeat (LTR) promoter. The nuclei
killing. Standard methods for quantitatively measuring of infected cells stain blue after incubation with X-gal,
infectious HIV and SIV typically require infection and and individual infected cells are counted in situ with the
spread of the virus in T-cell lines, and replication differ- aid of a light microscope. Unfortunately, this assay also
ences can make the comparison of phenotypically dis- has limitations; the HeLa-CD4-LTR-b-gal cell line devel-
tinct strains problematic. Similarly, protocols that mea- oped by Kimpton and Emerman [called the multinuclear
sure infectious virus by cytopathic effect or syncytia, for activation of a galactosidase indicator (MAGI) cell line] is
example, neutralization assays, will be biased against not sensitive to infection by most primary HIV-1 isolates
viral isolates that are noncytopathic or nonsyncytia induc- (Kimpton and Emerman, 1992). In addition, one report
ing. Other than the viral receptor, the cellular factors that indicates that HeLa-CD4 cells are moderately suscepti-
determine viral tropism and syncytia-inducing ability are ble to SIVagm and, to a lesser extent, SIVmac infection
largely uncharacterized. (Rocancourt et al., 1990), but we have found that the
Human cell lines engineered to express human CD4 HeLa-CD4 (MAGI) cell line is not susceptible to SIVM-
can be infected by HIV type 1 (HIV-1) to varying degrees neCL8 infection (Chackerian and Overbaugh, unpub-
(Cheng-Mayer, 1990; Clapham et al., 1991). Similarly, lished observations).
assays that require only a single round of infection to Recently, Goldstein et al. (1995) reported that a rhesus
detect infectious HIV-1 in CD4 cell lines (Chesebro and macaque cell line expressing human CD4 (CMMT-CD4)
is sensitive to SIVsm, SIVmac, and SIVagm infection
(Goldstein et al., 1995). In addition, previous studies had1 To whom correspondence and reprint requests should be ad-
dressed. shown the SIV Tat protein can efficiently transactivate
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the HIV-1 LTR (Viglianti and Mullins, 1988). On the basis high CD4 expression one additional time (as described
above).of these observations, we engineered the CMMT cell line
to carry the human CD4 gene and an HIV-1-LTR-b-gal
Viruses and infectionsreporter gene. This cell line, the simian MAGI (sMAGI) line,
is highly sensitive to infection by T-cell- and macrophage-
SIV stocks were prepared by infecting CEM 1 174
tropic SIV strains, as well as primary and laboratory-
cells, C8166 cells, or Macaca nemestrina peripheral
adapted isolates. Using these indicator cells the titer of
blood mononuclear cells (PBMCs) with cell-free virus and
neutralizing antibody activity in macaque plasma against
culturing for 2 to 4 weeks. Cells were cultured in RPMI
three commonly used SIV isolates was determined. Our
1640 supplemented with 10% fetal calf serum, 100 U per
analysis showed that this approach can be used to define
milliliter penicillin, 100 mg per milliliter streptomycin, 1
neutralizing antibody titers to homologous and heterolo-
mM sodium pyruvate, and 100 mM nonessential amino
gous virus isolates. We also tested the sensitivity of the
acids; 1% phytohemagglutinin-M and 50 U per milliliter
sMAGI cell line to isolates of HIV-1 and HIV-2. The cell
interleukin-2 were added to PBMCs in culture. Cell-free
line was not susceptible to infection by either cloned or
virus was harvested from the cultures by low-speed cen-
primary isolates of HIV-1. But, the sMAGI cells were sensi-
trifugation for 5 min to remove the majority of cells fol-
tive to infection by some strains of HIV-2.
lowed by filtration through a 0.22 mM filter. Viral stocks
harvested from CEM 1 174 cells include the following:
SIVMneCL8 (Morton et al., 1989; Overbaugh et al., 1991),MATERIALS AND METHODS
a cloned cytopathic and syncytia-inducing variant of SIV-
Cell lines MneCL8, SIVMne170 (Kimata and Overbaugh, unpub-
lished observations), a chimeric virus M87004 35wk,
CMMT cells (a rhesus macaque mammary tumor cell
which was constructed by inserting the majority of gp120
line) were obtained from the American Type Culture Col-
from clone 35wk:1-1 (Overbaugh et al., 1991) into an SIV-
lection (Rockville, MD). Cells were grown in Dulbecco’s
MneCL8 background (Rudensey and Overbaugh, unpub-
modified Eagle’s medium (DMEM) supplemented with
lished observations), SIVmac239 (Kestler et al., 1990),
10% fetal calf serum, 100 U per milliliter penicillin, 100
and an uncloned virus pool, SIVsmE660 (Hirsch and
mg per milliliter streptomycin, and 300 mg per milliliter
Johnson, 1994). SIVmac1A11 (Marthas et al., 1989, 1990)
glutamine (complete DMEM). CMMT-CD4 cells were
and uncloned SIVMne (Benveniste et al., 1986) were
constructed by infecting CMMT cells with the ampho-
grown in macaque PBMCs. Primary isolates derived from
tropic retroviral vector PA317/LT4SN (Kimpton and Emer-
the PBMCs of an infected M. nemestrina (M87004) 170
man, 1992; McElrath et al., 1994). Cells were selected
weeks postinoculation and passaged through CEM 1
by growth in complete DMEM plus 0.2 mg per milliliter
174 cells, C8166 cells, or macaque PBMCs were de-
gentamycin (G418, at an active concentration of 700 mg
scribed previously (Rudensey et al., 1993).
per milligram; GIBCO, Grand Island, NY). From the G418-
Cell free HIV-2 EHO, HIV-2 KR, and HIV-2 ROD stocks
resistant cell population, we used fluorescence-activated
were grown in U937 cells, CEM 1 174 cells, and human
cell sorting (FACS) to segregate the top 15–30% of cells
PBMCs, respectively. HIV-1 LAI was grown in CEM 1
that expressed the highest surface levels of CD4, as was
174 cells and human PBMCs. HIV-1 BAL was grown in
done with the original MAGI cells (Kimpton and Emer-
human PBMCs. WH91-330 was passaged through hu-
man, 1992). To further purify this high CD4-expressing
man PBMCs (White-Scharf et al., 1993). Primary isolates
subpopulation, the cells were resorted for high CD4 ex-
MM1-2201 and BB2-2847 from a Kenyan woman and
pression by FACS after culturing for an additional 2 and
infant, respectively, were obtained by coculturing their
4 weeks under G418 selection.
PBMCs with donor human PBMCs for 4 weeks (Welch,
CMMT-CD4-LTR-b-gal indicator cells were con-
Kreiss, and Overbaugh, unpublished observations). The
structed by transfecting CMMT-CD4 cells with plasmid
following reagents were obtained through the AIDS Re-
pEQ447 (Harrington and Geballe, 1993) using Lipofectin
search and Reference Reagent Program, Division of
(GIBCO BRL, Gaithersburg, MD). pEQ447 contains the
AIDS, NIAID, NIH: p239SpE3 * and p239SpSp5* from Dr.
hygromycin resistance gene under the control of the cyto-
Ronald Desrosiers (Kestler et al., 1990), HIV-2 CBL-20/
megalovirus major immediate-early promoter, the b-gal
H9 from Dr. Robin Weiss (Schulz et al., 1990), and HIV-
gene downstream of a truncated HIV-1 LTR, and the sim-
2 D194/HUT-78 from Dr. Hagen von Briesen (Kuhnel et
ian virus 40 T antigen nuclear localization signal. Cells
al., 1989; von Briesen et al., 1990).
were grown in complete DMEM plus 0.2 mg per milliliter
of G418 (at an active concentration of 700 mg per milli- Virus assays
gram) and 50 U per milliliter hygromycin (Calbiochem,
La Jolla, CA) in order to isolate single cell clones. Thirty The CMMT-CD4-LTR-b-gal indicator cells were plated
in 12-well plates at 4 1 104 cells per well in completeof the G418 and hygromycin-resistant colonies were ex-
panded in culture, and subsequently the two clonal cell DMEM the day before infection. The cells were infected by
removing the media from each well and adding dilutions oflines that we chose for further study were sorted for
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virus in a total volume of 300 ml of complete DMEM with against Vn/V0 , and the dilution that reduced Vn to 10% of
V0 (Vn/V0  0.1) was scored as the neutralizing titer, as15 mg per milliliter DEAE-Dextran. Some infections were
also performed in the presence of 5 mM AZT (Sigma, St. described by Nara et al. (1987). As a negative control,
prebleed plasma from all three animals was testedLouis, MO). Two hours after infection, an additional 1.5 ml
of complete DMEM was added to each well. Three days against each virus. Scoring of blue nuclei in a 96-well
format was greatly enhanced using an eyepiece reticulelater, the medium was removed and cells were fixed with
1–2 ml of 1% formaldehyde–0.2% glutaraldehyde in phos- (101 10 grid) and a planar lens (Zeiss 2.51) to visualize
the entire well.phate-buffered saline (PBS) for 5 min. Cells were then
washed twice with PBS and stained with 600 ml of 4 mM The levels of antibody specific for SIV gp160 were
determined by ELISA, as described previously (Haig-potassium ferrocyanide, 4 mM potassium ferricyanide, 1
mM magnesium chloride, 0.4 mg per milliliter 5-bromo-4- wood et al., 1992b; Planelles et al., 1991), with the follow-
ing modification: recombinant SIVMneCL8 envelopechloro-3-indolyl-b-D-galactopyranoside (X-gal) in PBS for
50 min at 377 in a non-CO2 incubator. The staining was gp160 was purified from vaccinia virus-infected cells in-
fected with Vac-160 (Hu et al., 1995).stopped by removing the staining solution and washing
thoroughly at least two times with PBS.
The infectious titer of some viral supernatants was RESULTS
also determined by endpoint dilution of virus in CEM 1
Identification of sMAGI cell lines174 cells. CEM 1 174 cells were infected with serial
threefold dilutions of virus in triplicate. Productive virus We engineered the CMMT adherent rhesus macaque
infection was detected by assaying for SIV p27gag antigen mammary tumor cell line to express human CD4 and an
2 weeks after infection by Enzyme Immunoassay as de- HIV-1 LTR-b-gal fusion. We examined the susceptibility
scribed by the manufacturer (Coulter, Hialeah, FL). A tis- to SIV infection of randomly chosen G418 (linked to CD4)
sue culture infectious dose (TCID) was defined as the and hygromycin-B (linked to LTR-b-gal) resistant clones
maximum dilution of virus where one of the CEM 1 174 by scoring blue nuclei in cells infected with SIVMneCL8.
cultures became infected. To exclude clones with a high background of cells ex-
pressing detectable b-gal activity, we also examined un-
Neutralization assays infected cells for blue nuclei. Of the 30 CMMT-CD4-LTR-
b-gal clones that we analyzed, 2 (clones 19 and 21) had
Plasma samples were obtained from two M. nemes- reproducibly high numbers of blue nuclei after infection
trina (animals 93100 and 92263) infected with SIVMne, with SIVMneCL8 (Fig. 1A) and a low number of blue
an uncloned mixture from which SIVMneCL8 was derived nuclei after mock-infection (Fig. 1B). We used clone 21
(Benveniste et al., 1986), and a Macaca mulatta (animal for subsequent experiments because there was a slightly
176) infected with SIVsmE660 (Hirsch and Johnson, 1994) lower number of background blue nuclei in uninfected
(grown in macaque PBMCs). Plasma samples were ob- cells. Based on the similarities between these cells and
tained both prior to infection (prebleed) and 6 to 8 months the MAGI cells described by Kimpton and Emerman
postinoculation. All plasma samples were heat-inacti- (1992), we renamed the CMMT-CD4-LTR-b-gal (clone 21)
vated for 30 min at 567. sMAGI cells were added to a 96- cells the simian MAGI (sMAGI) cell line.
well plate 24 hr prior to infection at a density of 3.5 1
103 cells per well. The following day, plasma was serially Sensitivity of the sMAGI cells to SIV infection
diluted twofold in complete DMEM to a final volume of
25 ml and added to an equal volume of virus. Typically, We tested the sensitivity of the sMAGI cells to SIV
infection by comparing the infectious titer of SIVMneCL8virus stocks were diluted in complete DMEM to 100–
200 infectious particles per 25 ml. The virus/plasma mix- by sMAGI assay versus limiting dilution in CEM 1 174
cells, a cell line highly susceptible to SIV infection.ture was incubated at 377 in a 5% CO2 incubator. After
45 min, medium was removed from the sMAGI cells, and sMAGI cells were infected with seven dilutions of virus
in duplicate. At 3 days, cells were stained and a sMAGIthen the sMAGI cells were infected with the virus/plasma
mixture. At the time of infection, DEAE-Dextran was infectious dose was determined by counting the number
of blue infectious centers. Clusters of blue nuclei foundadded to the virus/plasma mixture at a final concentration
of 15 mg per milliliter. After 2 hr of infection, an additional in syncytia or dense clusters of blue nucleated cells,
which probably result from the replication of infected200 ml of complete DMEM was added. Three days after
infection, medium was removed and the cells were fixed cells, were scored only once. Typically, infections of
sMAGI cells with viral dilutions that result in 50 to 1000and stained as described above. Neutralization was
scored by comparing the average number of blue infec- blue cells can be counted accurately in 12-well plates
and are in the linear range of the assay (data not shown).tious centers in two wells in the presence of test plasma
(Vn) with the number of infectious centers in the absence In 12-well plates, an average of 5 blue nuclei, based on
25 experiments, were observed in uninfected controlsof plasma (V0). In each experiment, replicas of eight were
used to determine the average V0 . Dilutions were plotted (data not shown). The sMAGI infectious titer of this stock
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FIG. 1. Activation of b-gal expression in SIV-infected sMAGI cells. Cells were infected, fixed, and stained as described under Materials and
Methods. SIVMneCL8- (A) or mock (B)-infected cells are shown. Magnification, 1200.
of SIVMneCL8 was 5 1 104 per milliliter. The TCID of SIV isolates differ in tropism and replication rate in
different cell lines. To assess the infectivity of the sMAGIthis virus stock was determined in parallel in CEM 1
174 cells and was also 5 1 104 per milliliter (Table 1A). cell line, we tested six CEM 1 174-derived virus stocks,
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TABLE 1 that rapidly replicating strains of SIV, like SIVmac239 and
the M87004 170wk pool, may spread in the sMAGI cellsQuantitative Analysis of SIV Infectious Dose by sMAGI Assay
during the 3-day infection and inflate calculations of virusCompared to Endpoint Dilution Infection in CEM 1 174 Cells
titer. To test this, we infected sMAGI cells with similar
sMAGI CEM 1 sMAGI titer numbers of infectious particles (approximately 100) of
Virus titer a 174 titer b CEM titer SIVmac239, SIVMneCL8, or the M87004 170wk pool.
Some sMAGI cells were infected in the presence of 5A
mM AZT, which inhibits virus replication at the step ofSIVMneCL8 5 1 104 5 1 104 1
SIVMne170 1 1 104 5 1 103 2 reverse transcription and thus limits virus spread. As a
M87004 35wk 2 1 105 5 1 104 4 control, AZT was added prior to infection, and only one
M87004 170wk 2 1 106 5 1 105 4 to three blue nuclei were observed in these cells (data
SIVsmE660 2 1 105 1 1 105 2
not shown), indicating that the amount of AZT added wasSIVmac239 4 1 104 5 1 103 8
sufficient to inhibit infection. AZT was added at 24 or
B 48 hr after infection to prevent virus spread. Cells were
M87004 170wk[CEM 1 174] 2 1 106 5 1 105 4
stained and counted 72 hr after infection. Based on stud-M87004 170wk[C8166] 2 1 106 5 1 105 4
ies of HIV-1 kinetics, most of the infectious particles inM87004 170wk[PBMC] 3 1 104 3 1 104 1
SIV mac1A11[PBMC] 2 1 105 1 1 105 2 the original inoculum infect cell lines during the first 12
hr of infection (Kim et al., 1989; Pellegrino et al., 1991).
a Number of blue nucleated cells per milliliter of cell-free virus stock. Thus, at 24 hr we would expect most of the original virusb TCID per milliliter, computed as described under Materials and
that was infectious to have entered the cell. TreatmentMethods.
with AZT at this point would be predicted to inhibit virus
spread, but not affect infection of the original inoculum.
representing a wide variety of SIV isolates from the To analyze virus spread in the sMAGI cells, we compared
SIVsm/SIVmac/SIVMne group of primate lentiviruses, for the number of infected cells when AZT was added at 24
their ability to infect the sMAGI cell line. The viruses hr with the number of infected cells when AZT was added
included T-cell [SIVmac239 (Banapour et al., 1991a,b) later. The number of blue nuclei were counted in infec-
and M87004 170wk (Rudensey et al., 1995)]- and macro- tions treated with AZT at 24 and 48 hr and in the untreated
phage-tropic [SIVmac1A11 (Banapour et al., 1991a,b) and culture. In Fig. 2 these data are normalized by dividing
SIVMneCL8 (Rudensey et al., 1995)] SIV isolates. We the number of blue nucleated (infected) cells scored in
compared the sMAGI infectivity titer of the six CEM 1 each case by the number of blue cells scored in wells
174-derived virus stocks with the TCID obtained by lim- in which infected cells were treated with AZT 24 hr after
iting dilution infection of the CEM 1 174 cell line. These infection. Infection with SIVmac239 resulted in a steady
results are summarized in Table 1A. The sMAGI infec- increase in the number of blue cells; there were approxi-
tious dose was always the same or higher (up to eight- mately 1.5 times more blue nucleated cells after 2 days
fold) than the TCID in CEM 1 174 cells. We consistently of infection (treatment with AZT at 48 hr) and 2.5 times
observed an eightfold difference between assays with more blue nucleated cells after 3 days of infection (no
SIVmac239. AZT) (Fig. 2), indicating that SIVmac239 spread in the
In order to determine whether viruses expressed in
different cells are equally infectious for sMAGI cells, the
infectious titer of stocks of the T-cell-tropic M87004
170wk SIVMneCL8 variant mixture grown in either C8166
cells or macaque PBMCs was determined using the
sMAGI assay and CEM 1 174 endpoint dilution (Table
1B). These stocks (as well as the M87004 170wk pool
grown in CEM 1 174 cells) contain very similar popula-
tions of virus (Rudensey et al., 1993). We also tested the
macrophage-tropic clone SIVmac1A11 grown in ma-
caque PBMCs. Again, the sMAGI assay shows similar
sensitivity in comparison with the endpoint dilution
method for each of these virus isolates; sMAGI infectious
titers were equal to or up to fourfold greater than the
TCID in CEM 1 174 cells. FIG. 2. Comparison of the infection kinetics of SIVMneCL8, M87004
170wk [CEM 1 174], and SIVmac239 in sMAGI cells. Cells were in-
Titers of rapidly replicating SIV strains may be slightly fected in triplicate for 3 days. To compare the extent of virus spread,
we normalized the data by dividing the number of blue nucleated cellsinflated using the sMAGI assay
scored in each case by the number of blue cells scored in wells in
The sMAGI assay measures the number of infectious which infected cells were treated with AZT 24 hr after infection. Error
bars indicate the SD of the data.particles during a 3-day infection. The possibility exists
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at a low level (1:8 and 1:14) and both neutralized SIV-
mac239 at a low but detectable level (1:4). Plasma from
the SIVsmE660-infected macaque neutralized SIV-
smE660 at a titer of 1:140, but failed to show any neu-
tralizing activity against SIVMne or SIVmac239. Prebleed
plasma from all three animals failed to neutralize any of
the SIV isolates tested (titer of 1:4), demonstrating that
neutralizing antibodies are specific to SIV. All three of
the animals tested had no clinical signs of AIDS at the
time of testing and the pattern of antibody production
represented typical humoral immune responses (data not
shown).
HIV-1 and HIV-2 infection of sMAGI cells
FIG. 3. Neutralization of SIVMne with diluted plasma from macaques Because the sMAGI cells were susceptible to infection
92263, 93100, and 176. Neutralization was scored for each sample by by all isolates of SIV examined, we tested the sensitivity
determining the value Vn/V0 , where Vn is the average number of blue of the sMAGI cell line to infection by other primate lentivi-
nuclei in the presence of test plasma, and V0 is the number of blue
ruses, HIV-1 and HIV-2. We determined the infectivity ofnuclei in the absence of plasma. Plasma from (m) Macaque 92263, (l)
several strains of HIV-1 and HIV-2 in the simian CMMT-Macaque 93100, and (j) Macaque 176.
CD4 (sMAGI) cells compared to the human HeLa-CD4
(MAGI) cells (Kimpton and Emerman, 1992), CEM 1 174
sMAGI cells during the 3-day assay period. Thus, the cells, or human PBMCs (Table 3). The sMAGI cells were
infectious titer of SIVmac239 may be slightly inflated not sensitive to infection by either of the laboratory-
when using the sMAGI assay. If this inflation was taken adapted HIV-1 strains that we tested, HIV-1 BAL (grown
into account, sMAGI infectious titers of SIVmac239 were in CEM 1 174 cells) and HIV-1 LAI (grown in both CEM
about 3 times higher than the TCID on CEM 1 174 cells, 1 174 cells and human PBMCs), nor were they suscepti-
which is in the range (i.e., 1- to 4-fold) of the other isolates ble to infection by several primary isolates of HIV-1. Cells
that we tested. Thus, accurate sMAGI infectious titers of were infected with 5 to 100 ml of two uncharacterized
SIVmac239 may be obtained by treating infected sMAGI mixtures of virus isolated from HIV-1-seropositive Kenyan
cells with AZT 24 hr after infection. SIVMneCL8 and the individuals (MM1-2201 and BB2-2847) and one uncharac-
M87004 170wk pool spread slowly in the sMAGI cell line, terized mixture isolated from an HIV-1-seropositive Amer-
as indicated by the fact that the number of infected cells ican (WH91-330). We observed background numbers of
stayed fairly constant whether AZT was added at 24 hr blue nuclei when we infected with any of these virus
or not (Fig. 2). Thus, viral spread did not dramatically populations, even if the sMAGI cells were passaged for
influence our calculations of the sMAGI infectious titer a week after infection before staining.
of these virus isolates. In contrast, the sMAGI cell line was susceptible to
HIV-2 infection, although the infectivity varied among the
Neutralization assay using sMAGI cells strains that we tested (Table 3B). The infectivity titers of
HIV-2 strains KR and CBL-20 were approximately 100-
We were interested in determining the extent of neu- fold lower by the sMAGI assay compared to the MAGI
tralizing activity of plasma from macaques infected with assay or endpoint dilution on human PBMCs. However,
different strains of SIV against homologous and heterolo- sMAGI cells were relatively more sensitive to infection
gous virus. Plasma from two M. nemestrina infected with by HIV-2 strains EHO, ROD, and D194; infectivity titers
uncloned SIVMne or a M. mulatta infected with SIV- were about 5- to 10-fold less by the sMAGI assay com-
smE660 was tested for virus neutralization activity pared to the MAGI assay or endpoint dilution on human
against SIVMne, SIVsmE660, and SIVmac239 (all grown PBMCs. The infectivity for the sMAGI cells correlates
on CEM 1 174 cells) using the sMAGI assay. Plasma with their relative ability to infect macaque PBMCs, and
was tested in duplicate, using twofold dilutions from 1:4 both HIV-2 EHO and HIV-2 ROD have been shown to
to 1:8192. Figure 3 demonstrates the range of the assay persistently infect rhesus macaques (Livartowski et al.,
for neutralization of SIVMne. SIVMne was strongly neu- 1992).
tralized by plasma from both of the macaques infected
with SIVMne, at titers of 1:200 and 1:80, but not neutral- DISCUSSION
ized by plasma from the SIVsmE660-infected macaque
(titer of 1:4). Plasma neutralization of all three virus We have developed a rhesus macaque cell line that
has broad sensitivity to infection by numerous SIV iso-strains is shown in Table 2. While neutralization of SIV-
Mne was the highest in the SIVMne-infected macaques, lates as well as some sensitivity to HIV-2 infection and
is useful in detecting infectious virus after a single cycleboth sets of plasma also cross-neutralized SIVsmE660
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TABLE 2
Neutralization Titers of Plasma versus SIVMne, SIVsmE660, and SIVmac239
Neutralization titer against a
Animal Time of Env ELISA SIV
(infected with) sample titer b SIVMne smE660 SIVmac239
93100 Prebleed 100 4 4 4
(SIVMne) 6 months p.i.c 16,000 200 14 4
92263 Prebleed 100 4 4 4
(SIVMne) 6 months p.i. 15,000 80 8 4
176 Prebleed 100 4 4 4
(SIV smE660) 6 months p.i. 2500 4 140 4
a 90% neutralization, as described in the text.
b As described under Materials and Methods.
c p.i., postinoculation.
of viral replication. The CMMT line was initially chosen ters with some viruses may be circumvented by the addi-
because previous reports indicated that a CMMT-CD4 tion of AZT to sMAGI cells 24 hr after infection. Thus, for
line is permissive for SIV infection (Goldstein et al., 1995; all the SIV isolates that we tested, the determination of
Hirsch et al., 1994). The sMAGI cells are sensitive to infectious titer by the sMAGI assay is a highly sensitive
infection by all the SIV strains that we tested, including and reproducible alternative to endpoint dilution in CEM
(1) virus propagated in CEM 1 174 cells, C8166 cells, 1 174 cells.
and macaque PBMCs, (2) molecular clones and un- A key advantage of the sMAGI cells is that detection of
cloned mixtures, (3) cell-line-adapted and primary iso- virus requires only one round of viral replication. Because
lates, and (4) T-cell- and macrophage-tropic isolates. these cells allow us to directly compare a broad spec-
sMAGI infectious titers were consistently one- to eight- trum of viral isolates that have different replication rates,
fold higher than the TCID defined by endpoint dilution in the sMAGI assay is ideally suited to determine neutraliz-
CEM 1 174 cells. In the case of the virus (SIVmac239) ing titers against different SIV isolates. Neutralization
which yields an eightfold higher sMAGI infectious titer, assays described to date (reviewed by D’Souza et al.,
a portion of this difference could be attributed to virus 1993) have utilized human cell lines or hybrid cell lines,
spread in the sMAGI cells over the 3-day incubation pe- such as CEM 1 174, and readouts that are indirect, such
riod. The tendency for moderately inflated infectious ti- as antigen production (Haigwood et al., 1992a; Planelles
et al., 1991) or cytopathic effects (Montefiori et al., 1988).
Another widely applied assay that measures the inhibi-
TABLE 3
tion of syncytium induction by SIVmac251 is limited to
Sensitivity of Detection of HIV-1 and HIV-2 Isolates by the sMAGI studies with that virus isolate (Langlois et al., 1991). Here,
Assay versus Other Assays
we demonstrate the ability of the sMAGI neutralization
assay to quantitate neutralizing antibody titers. We showVirus sMAGI Titer Titer
the reactivity of neutralizing antibody from a macaque
A infected with one SIV strain against other common SIV
HIV-1 BAL 0 1 1 106 a strains. We can detect homologous as well as heterolo-
HIV-1 LAI [PBMC] 0 1 1 106 b,c
gous neutralizing activity because the sMAGI cells areHIV-1 LAI [CEM] 0 1 1 107 b,c
equally susceptible to infection by diverse SIV isolates.HIV-1 (MM1-2201) 0 ndd
HIV-1 (BB2-2847) 0 nde Thus, this single-cycle infection assay circumvents previ-
HIV-1 WH91-330 0 1 1 107 a ous difficulties in detecting the breadth of neutralizing
activity in SIV-infected macaques to different variants.B
HIV-2 KR 8 1 102 2 1 105 a,c Clearly, the sMAGI neutralization assay is adaptable
HIV-2 CBL-20 5 1 103 2 1 105 c for testing neutralizing activity using all three of the com-
HIV-2 EHO 2 1 105 1 1 106 a,c
monly utilized SIV isolates, as well as subclones of theseHIV-2 ROD 2 1 103 2 1 104 a,c
isolates. In addition, this assay maintains several of theHIV-2 D194 2 1 103 1 1 104 c
advantages of a commonly used assay to detect HIV-1
a TCID per milliliter in human PBMC. neutralization (Nara et al., 1987). The sMAGI neutraliza-
b TCID per milliliter in CEM 1 174 cells. tion assay allows direct measurements of infectivity thatc Infectious dose by MAGI assay (blue cells per milliliter).
are scored visually, the 3-day assay period is relativelyd Approximately 300 ng p24gag per milliliter.
e Approximately 70 ng p24gag per milliliter. short, and the assay yields statistically significant results.
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Chesebro, B., and Wehrly, K. (1988). Development of a sensitive quanti-The sMAGI neutralization assay will be useful in quantita-
tative focal assay for human immunodeficiency virus infectivity. J.tively comparing the homologous and heterologous neu-
Virol. 64, 4553–4557.
tralizing activity in macaques at various stages of disease Clapham, P. R., Blanc, D., and Weiss, R. A. (1991). Specific cell surface
progression. requirements for the infection of CD4-positive cells by human immu-
nodeficiency virus types 1 and 2 and by simian immunodeficiencyThe primate lentiviruses SIV, HIV-2, and HIV-1 share
virus. Virology 181, 703–715.the same cellular receptor, CD4 (Dalgleish et al., 1984;
Dalgleish, A. G., Beverley, P. C., Clapham, P. R., Crawford, D. H.,Klatzmann et al., 1984; Sattentau et al., 1988). However,
Greaves, M. F., and Weiss, R. A. (1984). The CD4 (T4) antigen is an
these three viruses have distinct infectivity requirements essential component of the receptor for the AIDS retrovirus. Nature
in many human and nonhuman CD4/ cell lines. For ex- 312, 763–767.
Dragic, T., and Alizon, M. (1993). Different requirements for membraneample, the CMMT-CD4 cell line is susceptible to SIV
fusion mediated by the envelopes of human immunodeficiency virusinfection, but it is only partially sensitive to HIV-2 infection
types 1 and 2. J. Virol. 67, 2355–2359.and is not sensitive to HIV-1 infection. In contrast, the
D’Souza, M. P., Kent, K. A., Thiriart, C., Collignon, C., and Millman,
HeLa-CD4 cell line is susceptible to infection by HIV-2 G. (1993). International collaboration comparing neutralization and
and many T-cell-tropic HIV-1 strains, but not macro- binding assays for monoclonal antibodies to simian immunodefi-
ciency virus. AIDS Res. Hum. Retroviruses 9, 415–422.phage-tropic HIV-1 or some SIV strains. SIV and HIV-2
Felber, B. K., and Pavlakis, G. N. (1988). A quantitative bioassay forhave a similar ability to infect or induce cell fusion in a
HIV-1 based on trans-activation. Science 239, 184–187.number of engineered CD4/ primate and nonprimate cell
Fenyo¨, E. M., Albert, J., and Asjo¨, B. (1989). Replicative capacity, cyto-
lines, including U87/CD4/ glioma cells (Clapham et al., pathic effect and cell tropism of HIV. AIDS 3, s5–s12.
1991; Dragic and Alizon, 1993) and CD4/ cat and mink Goldstein, S., Hague, B., Montefiori, D., and Hirsch, V. (1995). A ma-
caque adherent cell line that expresses human CD4 is susceptiblecell lines (McKnight et al., 1994). Thus, these and our
to SIV: Utility for assessing neutralizing antibody. J. Virol. Methodsresults support the idea that SIV and HIV-2 share similar
53, 139–148.requirements for infectivity that are distinct, in some
Haigwood, N. L., Misher, L., Chin, S. M., Blair, M., Planelles, V., Scan-
cases, from HIV-1. SIV, however, appears to have a more della, C. J., Steimer, K. S., Gardner, M. B., Yilma, T., Hirsch, V. M.,
restricted host range than HIV-2 on HeLa-CD4 cells and and Johnson, P. R. (1992a). Characterization of group specific anti-
a number of other human cell lines (Clapham et al., 1991; bodies in primates: Studies with SIV envelope in macaques. J. Med.
Primatol. 21, 82–90.Koenig et al., 1989), but, SIV is more infectious for CMMT-
Haigwood, N. L., Nara, P. L., Brooks, E., Van-Nest, G. A., Ott, G., Higgins,CD4 cells. Because of differences in sensitivity to SIV,
K. W., Dunlop, N., Scandella, C. J., Eichberg, J. W., and Steimer, K. S.HIV-2, and HIV-1, the CMMT-CD4 cell line may be useful
(1992b). Native but not denatured recombinant human immunodefi-
for assessing viral and cellular determinants of infectivity. ciency virus type 1 gp120 generates broad-spectrum neutralizing
antibodies in baboons. J. Virol. 66, 172–182.
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